Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Int J Cancer. 2014 Jan 14;135(3):585–597. doi: 10.1002/ijc.28701

Fig. 4.

Fig. 4

Validation of altered expression of HNF1 network and ERalpha pathway genes in CCC and reactivation and demethylation of ERalpha pathway genes with Decitabine treatment. Quantitative RT-PCR of HNF1 network genes (HNF1A, F2, C14orf105 and SGK2) and ERalpha pathway genes (ESR1, CRIP1, SOX11, IGFBP4 and BMP4) using cell lines (A) and clinical samples (B). The expression of ERalpha pathway genes (ESR1, CRIP1, SOX11, IGFBP4 and BMP4) is markedly induced by demethylating agent 5-aza-2'-deoxycytidine, (Decitabine) in three CCC cell lines (RMG-5, KOC-7C, RMG-2) (C). Methylation at the ESR1 promoter is decreased in response to Decitabine treatment (D). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.